PIK3CD and cancer: The crosstalk and the efficacy of the double inhibition of the Hh and PI3K/Akt pathways have however been examined in several types of cancer and diseases (endometrial hyperplasia, medulloblastoma, pancreatic cancer staminal cells, renal cell carcinoma, glioma, esophageal adenocarcinoma, colorectal, breast cancer and prostate cancer): it has been demonstrated that the synergistic effect of the inhibition of the two pathways reduces cell growth, survival, chemoresistance, and tumor progression [71,72,73,74,75,76,77,78,79].